Paliperidone Sandoz (Paliperidone Palmitate)

Paliperidone palmitate, the active ingredient in Paliperidone Sandoz, is a atypical antipsychotic presented as a long‑acting injectable suspension for intramuscular use. It is indicated for the treatment of schizophrenia in adult patients. GNH USA supplies Paliperidone Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Paliperidone Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone palmitate is used in the management of schizophrenia, a chronic psychotic disorder that affects thought, perception and behavior.

- Schizophrenia: Reduces risk of relapse and helps maintain symptom control when administered as a monthly injection. - Schizoaffective disorder: Provides sustained antipsychotic coverage for patients who require long‑term stability. - Bipolar I disorder (maintenance): Assists as an adjunct to mood stabilisers to prevent manic episodes. - Schizophrenia maintenance after oral stabilization: Enables transition from oral therapy to a long‑acting injectable formulation. - Relapse prevention : Supports continued disease control in patients who have responded to oral paliperidone. - Acute symptom control : May be considered for rapid symptom stabilisation in acute episodes of schizophrenia.

The         …  ... ... ... ... ... ... ... ...